Scholars@Duke

Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure

Publication ,  Journal Article
Costa, LJ; Abbas, J; Hogan, KR; Kramer, C; McDonald, K; Butcher, CD; Littleton, A; Shoptaw, K; Kang, Y; Stuart, RK
Published in: Bone Marrow Transplantation
November 2012
Published version (DOI) Publisher Link

Duke Scholars

Yubin Kang
Author Yubin Kang Medicine, Hematologic Malignancies and Cellular Therapy
Altmetric Attention Stats
Dimensions Citation Stats

Published In

Bone Marrow Transplantation

DOI

10.1038/bmt.2012.60

EISSN

1476-5365

ISSN

0268-3369

Publication Date

November 2012

Volume

47

Issue

11

Start / End Page

1403 / 1408

Publisher

Springer Science and Business Media LLC

Related Subject Headings

  • Immunology
  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Costa, L. J., Abbas, J., Hogan, K. R., Kramer, C., McDonald, K., Butcher, C. D., … Stuart, R. K. (2012). Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplantation, 47(11), 1403–1408. https://doi.org/10.1038/bmt.2012.60
Costa, L. J., J. Abbas, K. R. Hogan, C. Kramer, K. McDonald, C. D. Butcher, A. Littleton, K. Shoptaw, Y. Kang, and R. K. Stuart. “Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.” Bone Marrow Transplantation 47, no. 11 (November 2012): 1403–8. https://doi.org/10.1038/bmt.2012.60.
Costa LJ, Abbas J, Hogan KR, Kramer C, McDonald K, Butcher CD, et al. Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplantation. 2012 Nov;47(11):1403–8.
Costa, L. J., et al. “Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.” Bone Marrow Transplantation, vol. 47, no. 11, Springer Science and Business Media LLC, Nov. 2012, pp. 1403–08. Crossref, doi:10.1038/bmt.2012.60.
Costa LJ, Abbas J, Hogan KR, Kramer C, McDonald K, Butcher CD, Littleton A, Shoptaw K, Kang Y, Stuart RK. Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplantation. Springer Science and Business Media LLC; 2012 Nov;47(11):1403–1408.

Published In

Bone Marrow Transplantation

DOI

10.1038/bmt.2012.60

EISSN

1476-5365

ISSN

0268-3369

Publication Date

November 2012

Volume

47

Issue

11

Start / End Page

1403 / 1408

Publisher

Springer Science and Business Media LLC

Related Subject Headings

  • Immunology
  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences